Ashley Cannon

5.4k total citations
38 papers, 1.5k citations indexed

About

Ashley Cannon is a scholar working on Neurology, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Ashley Cannon has authored 38 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Neurology, 14 papers in Physiology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Ashley Cannon's work include Alzheimer's disease research and treatments (11 papers), Amyotrophic Lateral Sclerosis Research (10 papers) and Neurofibromatosis and Schwannoma Cases (8 papers). Ashley Cannon is often cited by papers focused on Alzheimer's disease research and treatments (11 papers), Amyotrophic Lateral Sclerosis Research (10 papers) and Neurofibromatosis and Schwannoma Cases (8 papers). Ashley Cannon collaborates with scholars based in United States, United Kingdom and Switzerland. Ashley Cannon's co-authors include Dennis W. Dickson, Michael Hutton, Neill R. Graff‐Radford, Jennifer Gass, Stacey Melquist, Rosa Rademakers, Matthew Baker, Owen A. Ross, Stuart Pickering‐Brown and Jennifer Adamson and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and NeuroImage.

In The Last Decade

Ashley Cannon

34 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ashley Cannon United States 18 770 745 320 303 302 38 1.5k
Janna H. Neltner United States 20 497 0.6× 1.0k 1.4× 637 2.0× 641 2.1× 342 1.1× 29 1.8k
Martin Koller United States 9 402 0.5× 680 0.9× 338 1.1× 225 0.7× 339 1.1× 22 1.4k
John C. Janssen United Kingdom 18 395 0.5× 938 1.3× 540 1.7× 328 1.1× 399 1.3× 30 1.5k
Britta Brix Germany 17 268 0.3× 617 0.8× 484 1.5× 238 0.8× 264 0.9× 25 1.2k
Jamie Toombs United Kingdom 16 325 0.4× 588 0.8× 332 1.0× 185 0.6× 345 1.1× 27 1.2k
Luı́s F. Maia Portugal 17 541 0.7× 608 0.8× 210 0.7× 256 0.8× 706 2.3× 35 1.7k
Koji Kasanuki Japan 21 529 0.7× 522 0.7× 288 0.9× 315 1.0× 259 0.9× 55 1.2k
Linda Vedders United States 12 1.1k 1.4× 573 0.8× 273 0.9× 346 1.1× 255 0.8× 13 1.7k
Yumiko Motoi Japan 26 762 1.0× 625 0.8× 119 0.4× 272 0.9× 451 1.5× 76 1.9k
Steffen Halbgebauer Germany 19 598 0.8× 561 0.8× 294 0.9× 308 1.0× 443 1.5× 46 1.3k

Countries citing papers authored by Ashley Cannon

Since Specialization
Citations

This map shows the geographic impact of Ashley Cannon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashley Cannon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashley Cannon more than expected).

Fields of papers citing papers by Ashley Cannon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashley Cannon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashley Cannon. The network helps show where Ashley Cannon may publish in the future.

Co-authorship network of co-authors of Ashley Cannon

This figure shows the co-authorship network connecting the top 25 collaborators of Ashley Cannon. A scholar is included among the top collaborators of Ashley Cannon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashley Cannon. Ashley Cannon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gross, Andrea M., Lauren Baldwin, Ashley Cannon, et al.. (2025). Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib. JAMA Dermatology. 161(5). 533–533. 1 indexed citations
2.
Cannon, Ashley, Kavita Y. Sarin, Andrea Petersen, et al.. (2023). Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials. Clinical Trials. 21(1). 67–72.
3.
Radtke, Heather B., et al.. (2023). Parent perspectives on disclosing a pediatric neurofibromatosis type 1 diagnosis. Journal of Genetic Counseling. 32(5). 1088–1101.
4.
Cannon, Ashley, Whitley V. Kelley, Kelly M. East, et al.. (2023). Medical and psychosocial outcomes of state‐funded population genomic screening. Clinical Genetics. 104(4). 434–442. 2 indexed citations
5.
Kobayashi, Ihori, et al.. (2021). Blocking the orexin system following therapeutic exposure promoted between session habituation, but not PTSD symptom reduction. Journal of Psychiatric Research. 145. 222–229. 5 indexed citations
6.
Cannon, Ashley, Dominique C. Pichard, Pamela L. Wolters, et al.. (2021). Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas. Neurology. 97(7_Supplement_1). S15–S24. 8 indexed citations
7.
Radtke, Heather B., Amanda L. Bergner, Allison L. Goetsch, et al.. (2020). Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis—Practice Resource of the National Society of Genetic Counselors. Journal of Genetic Counseling. 29(5). 692–714. 15 indexed citations
8.
Cannon, Ashley, Peng Li, Kevin P. Boyd, et al.. (2018). Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet Journal of Rare Diseases. 13(1). 31–31. 42 indexed citations
9.
Pavlidakey, Peter, et al.. (2018). Unusual presentation of hereditary leiomyomatosis mimicking neurofibromatosis. JAAD Case Reports. 4(5). 440–441.
10.
Murray, Melissa E., Val J. Lowe, Neill R. Graff‐Radford, et al.. (2015). Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum. Brain. 138(5). 1370–1381. 236 indexed citations
11.
Clippinger, Amy K., Simon D’Alton, Wen-Lang Lin, et al.. (2013). Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. Acta Neuropathologica. 126(1). 39–50. 20 indexed citations
12.
Rutherford, Nicola J., Jada Lewis, Amy K. Clippinger, et al.. (2013). Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions. Brain Research. 1524. 62–73. 42 indexed citations
13.
Cannon, Ashley, Baoli Yang, Joshua A. Knight, et al.. (2012). Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction. Acta Neuropathologica. 123(6). 807–823. 45 indexed citations
14.
Sando, Sigrid Botne, Stacey Melquist, Ashley Cannon, et al.. (2008). Risk‐reducing effect of education in Alzheimer's disease. International Journal of Geriatric Psychiatry. 23(11). 1156–1162. 62 indexed citations
15.
Sando, Sigrid Botne, Stacey Melquist, Ashley Cannon, et al.. (2008). APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway. BMC Neurology. 8(1). 9–9. 194 indexed citations
16.
Reiman, Eric M., Kewei Chen, Richard J. Caselli, et al.. (2008). Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. NeuroImage. 40(3). 1214–1221. 26 indexed citations
17.
Dächsel, Justus C., Owen A. Ross, Ignácio F. Mata, et al.. (2006). Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathologica. 113(5). 601–606. 48 indexed citations
18.
Cannon, Ashley, Matthew Baker, Bradley F. Boeve, et al.. (2006). CHMP2B mutations are not a common cause of frontotemporal lobar degeneration. Neuroscience Letters. 398(1-2). 83–84. 50 indexed citations
19.
White, Stephen D., P. Bourdeau, Rod A.W. Rosychuk, et al.. (2001). Zinc‐responsive dermatosis in dogs: 41 cases and literature review. Veterinary Dermatology. 12(2). 101–109. 23 indexed citations
20.
Cannon, Ashley, et al.. (1960). Olfactory esthesioneuroepithelioma: report of a case.. PubMed. 87. 146–9. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janna H. Neltner Breakdown of academic impact, for papers by Martin Koller Breakdown of academic impact, for papers by John C. Janssen Breakdown of academic impact, for papers by Britta Brix Breakdown of academic impact, for papers by Jamie Toombs Breakdown of academic impact, for papers by Luı́s F. Maia Breakdown of academic impact, for papers by Koji Kasanuki Breakdown of academic impact, for papers by Linda Vedders Breakdown of academic impact, for papers by Yumiko Motoi Breakdown of academic impact, for papers by Steffen Halbgebauer
Rankless by CCL
2026